GSD logo

Devonian Health Group Inc. Stock Price

TSXV:GSD Community·CA$41.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

GSD Share Price Performance

CA$0.17
0.02 (9.68%)
CA$0.17
0.02 (9.68%)
Price CA$0.17

GSD Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet and good value.

2 Risks
1 Reward

Devonian Health Group Inc. Key Details

CA$31.0m

Revenue

CA$20.7m

Cost of Revenue

CA$10.3m

Gross Profit

CA$14.5m

Other Expenses

-CA$4.3m

Earnings

Last Reported Earnings
Apr 30, 2025
Next Reporting Earnings
n/a
-0.026
33.10%
-13.84%
0%
View Full Analysis

About GSD

Founded
n/a
Employees
7
CEO
Andre Boulet
WebsiteView website
groupedevonian.com

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.

Recent GSD News & Updates

The Market Lifts Devonian Health Group Inc. (CVE:GSD) Shares 31% But It Can Do More

Sep 11
The Market Lifts Devonian Health Group Inc. (CVE:GSD) Shares 31% But It Can Do More

Recent updates

No updates